Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on march 28, 2024. one individual was hired by adicet in march 2024 and granted new hire non-qualified stock options to purchase 99,400 shares of adicet's common stock with an exercise price of $2.35 per share, the closing price.
ACET Ratings Summary
ACET Quant Ranking